MedPageToday
MedPage Today) — AURORA, Colo. — Atosiban, an oxytocin receptor antagonist available in Europe, was not superior to placebo in improving neonatal outcomes for threatened preterm birth between 30 and 34 weeks’ gestation, according to the APOSTEL…
Read More
Trial Shines Light on Questionable Benefits of Tocolytics for Preterm Birth
Sharie Pekar
21:26
MedPage Today) — AURORA, Colo. — Atosiban, an oxytocin receptor antagonist available in Europe, was not superior to placebo in improving neonatal outcomes for threatened preterm birth between 30 and 34 weeks’ gestation, according to the APOSTEL…
